drugset / Trial / NCT02241187
Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
Completed
2 enrolled
Memorial Sloan Kettering Cancer Center
Cold Spring Harbor Laboratory · collabWeizmann Institute of Science · collab
NaSingle-groupOpen-labelTreatment
Summary
This study has several purposes. DCE-MRI will be used to image the tumor. Safety of cetuximab given before surgery will be studied. Cetuximab delivery to the tumor will be studied. In Stage 2 of this study, the safety of cetuximab and PEGPH20 given before surgery will be studied. Also, the effects of PEGPH20 on tumors will be studied.
Timeline
- Start
- 2014-09-12
- Primary completion
- 2016-09-13
- Completion
- 2016-09-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Pegvorhyaluronidase Alfa | Protein / enzyme biologic | 3 ug/kg | Intravenous |